Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTransense Regulatory News (TRT)

Share Price Information for Transense (TRT)

Share Price is delayed by 15 minutes
Get Live Data
55.50    -0.50 (-0.89%)
Bid:
55.00
Ask:
56.00
Spread: 1.00 (1.818%)
Market Cap: £8.45m
TRT Live PriceLast checked at - London Stock Exchange

Intraday Transense Share Chart

Share Repurchase Programme

27 Sep 2022 07:01

RNS Number : 7146A
Transense Technologies PLC
27 September 2022
 

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which is part of UK law by virtue of the European Union (withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

27 September 2022

 

Transense Technologies plc

("Transense", or "the Company")

 

Share Repurchase Programme

 

Transense Technologies plc (AIM: TRT), the developer of specialist sensor systems, is pleased to announce that it will commence a programme to conduct market purchases of ordinary shares of 10 pence each in the Company ("Ordinary Shares") up to a maximum aggregate purchase price of £650,000 (the "Programme").

 

The Company has entered into an arrangement with Shard Capital Stockbrokers ("Shard") in relation to the Programme where Shard will make the trading decisions concerning the timing of the market purchases of Ordinary Shares independently of and uninfluenced by the Company, with such trading decisions being in accordance with the terms of the Programme. Purchases may continue during any periods during the term of the Programme when the Company itself would be prohibited from dealing by the UK version of the Market Abuse Regulation 596/2014/EU (which is part of UK law by virtue of the European Union (Withdrawal) Act 2018) ("UK MAR"). The Company reserves the right to terminate the Programme if at any time it deems this to be appropriate and would make an announcement in advance of so doing.

 

The Company confirms that it currently has no unpublished inside information.

 

The Programme will commence today, 27 September 2022, and will continue until 30 November 2023 unless terminated earlier.

 

The Programme will be conducted by the Company in accordance with and under the terms of the general authority granted by the Company's shareholders at the Company's Annual General Meeting on 23 November 2021 to purchase up to 1,643,774 Ordinary Shares. This authority will expire at the earlier of the end of the next Annual General Meeting of the Company or 23 February 2023. Purchases under the Programme prior to the Annual General Meeting of the Company to be held on 1 December 2022 will be restricted to an aggregate of £150,000, and the balance of the Programme will continue after the Annual General Meeting subject to renewal of the appropriate authority by the shareholders.

 

Any market purchases will be conducted in compliance with the following restrictions regarding price conditions:

· the minimum price (exclusive of any expenses) at which any Ordinary Share may be purchased shall be its nominal value of 10 pence

· the maximum price (exclusive of any expenses) at which any Ordinary Share may be purchased shall be the higher of: (i) an amount equal to 5 per cent, above the average of the middle market quotations of an Ordinary Share as derived from the London Stock Exchange Daily Official List for the five business days immediately preceding the date of such purchase, and (ii) the higher of the price of the last independent trade and the highest current independent bid on the trading venue where the purchase is carried out.

 

Due to the limited liquidity in the Ordinary Shares, any market purchase of Ordinary Shares pursuant to the Programme on any trading day could represent a significant proportion of the daily trading volume in the Ordinary Shares on AIM and could exceed 25 per cent. of the average daily trading volume. This means that the Company will not benefit from the exemption contained in Article 5(1) of UK MAR.

 

The objective of the Programme is to offset the dilutive impact of share awards to directors and employees.

 

Ordinary Shares acquired as a result of the Programme will be held by the Company in treasury and in accordance with the Companies Act 2006, will not have any voting rights. It is anticipated that any Ordinary Shares held in treasury but surplus to unexercised option requirements from time to time will be cancelled.

 

For further information please visit www.transense.com or contact:

 

Transense Technologies plc

Nigel Rogers (Executive Chairman)

Melvyn Segal (CFO)

Via Walbrook PR

Allenby Capital (Nominated Adviser and Broker)

Jeremy Porter / George Payne (Corporate Finance)

Tony Quirke (Sales & Corporate Broking)

Tel: +44 (0)20 3328 5656

Walbrook PR

Tom Cooper / Nick Rome

Tel: +44 (0)20 7933 8780

Transense@walbrookpr.com

 

Notes to Editors:

Transense is a developer of specialist wireless sensor systems used to enable real-time data gathering and monitoring. Products include the patent protected Surface Acoustic Wave (SAW) sensor technology, used to improve equipment power, performance, reliability and efficiency; iTrack, Transense 's Tyre Pressure Monitoring System, licensed to Bridgestone Corporation, the world's largest tyre producer, under a ten-year deal in June 2020; and a range of intelligent tyre monitoring equipment under the Translogik brand. Target sectors include aerospace, electric motors & drives, industrial machinery and performance automotive. 

The Company's strategy is to maximise shareholder value through the delivery of sustained revenue growth from all three principal technologies - SAW, iTrack and Translogik probes - through leveraging excellence in innovation, know-how in commercialising technologies, industry partnerships and exposure to global growth markets.

Transense is headquartered in Oxfordshire, UK, and was admitted to trading on AIM, a market operated by the London Stock Exchange (AIM: TRT), in 1999.  www.transense.com.

For further information please contact transense@walbrookpr.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFEAARIRFIF
Date   Source Headline
23rd Nov 20117:00 amRNSOtraco iTrack Trial
21st Nov 201110:00 amRNSProposed Fundraising - Replacement
21st Nov 20117:00 amRNSProposed Fundraising
20th Oct 20117:00 amRNSContract - Pirelli Brazil
30th Sep 20117:00 amRNSHalf Yearly Report
28th Sep 20117:00 amRNSNew Trading Division
27th Sep 20117:00 amRNSShare Allotment
26th Sep 20117:00 amRNSUpdate
16th Sep 20118:38 amRNSDirector/PDMR Shareholding
16th Aug 201111:32 amRNSJoint Development Agreement - McLaren Electronics
23rd Jun 20092:48 pmRNSDirector/PDMR Shareholding
8th Jun 20097:00 amRNSRe Translogik Limited
29th Apr 20091:08 pmRNSJt Development with McLaren Electronic Systems Ltd
7th Apr 20097:00 amRNSFinal Results
6th Mar 200911:18 amRNSNotice of Preliminary Results
4th Feb 20095:00 pmRNSDirector/PDMR Shareholding
2nd Feb 20092:50 pmRNSGrant of Options
30th Jan 20092:37 pmRNSDirectorate Change
30th Jan 20091:47 pmRNSContract Win
12th Jan 20091:12 pmRNSHolding(s) in Company
22nd Dec 20083:33 pmRNSWaiver & Grant of New Options
12th Nov 200811:50 amRNSUpdate re Vectron International
21st Oct 20082:17 pmRNSHolding(s) in Company
20th Oct 200812:52 pmRNSDirector/PDMR Shareholding
17th Oct 20087:30 amRNSResponse to share price movement
13th Oct 200810:04 amRNSHolding(s) in Company
9th Oct 200810:09 amRNSHolding(s) in Company
19th Sep 200812:07 pmRNSHolding(s) in Company
16th Sep 20082:52 pmRNSDirector/PDMR Shareholding
4th Sep 20087:00 amRNSInterim Results
29th Aug 20083:45 pmRNSNotice of Results
26th Aug 20083:58 pmRNSHolding(s) in Company
30th Jul 200812:01 pmRNSHolding(s) in Company
29th Jul 20082:29 pmRNSHolding(s) in Company
15th Jul 20082:00 pmRNSRe Agreement
25th Jun 20087:00 amRNSDirector/PDMR Shareholding
2nd Jun 20087:19 amRNSDirectorate Change
15th Apr 20082:58 pmRNSDirector/PDMR Shareholding
15th Apr 200812:46 pmRNSPreliminary Results
10th Apr 20089:05 amRNSNotice of Results
4th Apr 20083:49 pmRNSHolding(s) in Company
3rd Apr 200812:47 pmRNSDirectorate Change
20th Mar 20084:24 pmRNSHolding(s) in Company
20th Mar 20084:19 pmRNSHolding(s) in Company-Amend
19th Mar 20084:00 pmRNSTotal Voting Rights
18th Mar 20082:49 pmRNSHolding(s) in Company
11th Mar 20085:43 pmRNSDirector Details
25th Feb 20082:41 pmRNSHolding(s) in Company
8th Feb 20087:30 amRNSDirector Declaration
8th Feb 20087:00 amRNSBoard and Adviser Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.